BMJ  2007;334:756-757 (14 April), doi:10.1136/bmj.39176.461227.80

Editorials

Composite and surrogate outcomes in randomised controlled trials

Composite end points may mislead—and regulators allow it to happen

The first 150 words of the full text of this article appear below.

In this week's BMJ, Ferreira-González and colleagues report that clinical trials may mislead if they use composite end points.¹ For example, a statement that an intervention reduces a composite end point of cardiovascular mortality, myocardial infarction, and revascularisation procedures is misleading if revascularisation procedures were more common outcomes than death or infarction, or if the intervention had a large apparent treatment effect on revascularisation but not on death or infarction.¹ It is not enough for people who use the research—doctors and patients—to be aware of such potential to mislead: pharmaceutical regulators should also examine their role.

Pharmaceutical regulation has provided benefit to society by harnessing the innovation of industry towards improving health. Pharmaceutical regulation helps to ensure that drugs are safe and achieve clinically relevant benefits for patients. Regulation also governs the manner in which drugs may be marketed to prescribers and to patients. It allows only claims that . . . [Full text of this article]

Health Care Evaluation Group, University of Birmingham, Birmingham B15 2TT

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Caveat emptor

Fiona Godlee
BMJ 2007 334: 0. [Extract] [Full Text]

Readers beware

Douglas Kamerow
BMJ 2007 334: 0. [Extract] [Full Text]

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials

Ignacio Ferreira-González, Gaiet Permanyer-Miralda, Antònia Domingo-Salvany, Jason W Busse, Diane Heels-Ansdell, Victor M Montori, Elie A Akl, Dianne M Bryant, Pablo Alonso-Coello, Jordi Alonso, Andrew Worster, Suneel Upadhye, Roman Jaeschke, Holger J Schünemann, Valeria Pacheco-Huergo, Ping Wu, Edward J Mills, and Gordon H Guyatt
BMJ 2007 334: 786. [Abstract] [Full Text] [PDF]

Validity of composite end points in clinical trials

Victor M Montori, Gaietà Permanyer-Miralda, Ignacio Ferreira-González, Jason W Busse, Valeria Pacheco-Huergo, Dianne Bryant, Jordi Alonso, Elie A Akl, Antònia Domingo-Salvany, Edward Mills, Ping Wu, Holger J Schünemann, Roman Jaeschke, and Gordon H Guyatt
BMJ 2005 330: 594-596. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Foley, P. W.X., Leyva, F., Frenneaux, M. P. (2009). What is treatment success in cardiac resynchronization therapy?. Europace 11: v58-v65 [Abstract] [Full text]  
• Sare, G. M., Gray, L. J., Bath, P. M.W. (2008). Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 29: 2031-2041 [Abstract] [Full text]  
• Starfield, B, Hyde, J, Gervas, J, Heath, I (2008). The concept of prevention: a good idea gone astray?. J. Epidemiol. Community Health 62: 580-583 [Abstract] [Full text]  
• Kip, K. E., Hollabaugh, K., Marroquin, O. C., Williams, D. O. (2008). The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.. J Am Coll Cardiol 51: 701-707 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Composite resources and value freedom

Grazyna T Adamiak
bmj.com, 11 May 2007 [Full text]

Online poll

Find out more here>> and here>>